jeudi 14 mars 2019

Onco Actu du 14 mars 2019


2.4 ETIOLOGIE - PORTABLES, ONDES E-M



Scientists Sign Petition Warning about EMF [Science-Based Medicine]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Statement from FDA Commissioner Scott Gottlieb, M.D., on advancing new policies aimed at preventing youth access to, and appeal of, flavored tobacco products, including e-cigarettes and cigars [FDA]











F.D.A. Moves to Restrict Flavored E-Cigarette Sales to Teenagers [NY Times]










U.S. proposes stricter curbs on e-cigarette sales [Reuters]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



Evidence-based web tool aims to better inform and refine need for treatment in early prostate cancer [University of Cambridge]











Online tool helps men choose best prostate cancer treatment [NHS ¢hoices]










4.12 BIOPSIES LIQUIDES



Genetron Health Adds Prospective Data on Early Detection of Viral Liver Cancer in Blood [Genome Web]











Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target [Xconomy]










4.2 DÉP., DIAG. & PRONO. - GÉNOME



Variant Calling Best Practices Benefit the Cancer Diagnostic Community [Cancer Therapy Advisor]











4.9 DÉP., DIAG. & PRONO. - SEIN



Rewriting the breast cancer rulebook [Cancer Research UK]










Molecular patterns could better predict breast cancer recurrence [Cancer Research UK]











Cancer's 'internal wiring' predicts relapse risk [BBC News]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



ZEB1 throttles therapeutic target, protecting KRAS-mutant lung cancer [MD Anderson Cancer Center]











5.10 TRAITEMENTS - ESSAIS



Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials [Xconomy]











FDA unveils 5 guidances on broadening cancer clinical trial eligibility [EndPoints]











5.2 PHARMA



Celgene's Abraxane fails late-stage pancreatic cancer study [Biopharma Dive]











Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer [Celgene]











Celgene’s chemotherapy Abraxane stumbles in pivotal pancreatic cancer study [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



A believer in biotech and big data: How Ned Sharpless vaulted to the top of the FDA [STAT]











5.4 TRAITEMENTS - ECONOMIE



Value extends beyond the cost of drugs and health care [STAT]











5.9.8 AACR - PHARMA



AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting [AstraZeneca]











6. LUTTE CONTRE LES CANCERS



Needed: A fully funded data federation for pediatric cancer with deep genomic sequencing and clinical records [The Cancer Letter]











Sharpless: With $500 million, NCI can create data federation that would change research in childhood cancer [The Cancer Letter]










Trump’s proposal for pediatric cancer has NCI envisioning the first data federation of its kind [The Cancer Letter]











St. Jude’s Roberts: “No single institution can maximize cures and minimize toxicities alone” [The Cancer Letter]











6.1 OBSERVATION



Nearly half of global childhood cancer cases go undiagnosed [Nature]











6.9 CONTROVERSES



California jury awards $29 million to woman with cancer who used J&J talc [Reuters]